Institutions / Privium Fund Management B.V. / Activity
Activity — Privium Fund Management B.V.
69 moves.
| Date | Action | Company | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|
| Q2 2026 as of | Add | Rocket Pharmaceuticals, Inc. Common stock | $253.1K | +74K +43.49% | 244,146 0.15% of portfolio | low |
| Q2 2026 as of | Add | TSHA Taysha Gene Therapies, Inc. Common Stock | $231.5K | +34K +20.62% | 198,900 0.25% of portfolio | low |
| Q2 2026 as of | Trim | RNAC Cartesian Therapeutics, Inc. Common Stock | $-217.0K | -21K -12.07% | 151,675 0.29% of portfolio | low |
| Q2 2026 as of | Add | Tidewater Inc Common stock | $213.2K | +3K +58.36% | 8,683 0.11% of portfolio | low |
| Q2 2026 as of | Trim | Tesla Inc Common stock | $-210.3K | -500 -0.22% | 228,000 17.62% of portfolio | low |
| Q2 2026 as of | Trim | NOV Inc Common stock | $-205.9K | -11K -20.89% | 42,026 0.14% of portfolio | low |
| Q2 2026 as of | Trim | Zai Lab Limited Common stock | $-190.0K | -10K -7.56% | 122,189 0.43% of portfolio | low |
| Q2 2026 as of | Trim | Lexeo Therapeutics, Inc. Common stock | $-175.0K | -38K -19.50% | 155,000 0.13% of portfolio | low |
| Q2 2026 as of | Trim | M96088105 Common stock | $-170.1K | -5K -2.15% | 210,000 1.42% of portfolio | low |
| Q2 2026 as of | New | CSAN Cosan S.A. ADR | $149.8K | +52K | 52,000 0.03% of portfolio | low |
| Q2 2026 as of | Add | Fate Therapeutics Inc Common stock | $122.1K | +45K +12.25% | 414,311 0.21% of portfolio | low |
| Q2 2026 as of | Add | H17182108 Common stock | $114.5K | +2K +4.90% | 44,974 0.45% of portfolio | low |
| Q2 2026 as of | Exit | Nomad Foods Ltd Common stock | $-102.6K | -8K -100.00% | 0 | low |
| Q2 2026 as of | Add | Voyager Therapeutics, Inc. Common stock | $87.5K | +25K +26.32% | 120,000 0.08% of portfolio | low |
| Q2 2026 as of | Add | AUTL Autolus Therapeutics plc ADR | $59.5K | +37K +11.40% | 363,430 0.11% of portfolio | low |
| Q2 2026 as of | Trim | G59665102 Common stock | $-52.5K | -4K -1.94% | 196,112 0.49% of portfolio | low |
| Q2 2026 as of | Trim | Beam Therapeutics Inc. Common stock | $-41.8K | -1K -1.70% | 70,282 0.44% of portfolio | low |
| Q2 2026 as of | Add | Transocean Ltd. Common stock | $29.3K | +6K +4.30% | 145,604 0.13% of portfolio | low |
| Q2 2026 as of | Add | Vertex Pharmaceuticals Inc / Ma Common stock | $22.4K | +45 +0.48% | 9,400 0.86% of portfolio | low |